Cargando…

Nutlin‐3a selects for cells harbouring TP 53 mutations

TP53 mutations occur in half of all human tumours. Mutagen‐induced or spontaneous TP53 mutagenesis can be studied in vitro using the human TP53 knock‐in (Hupki) mouse embryo fibroblast (HUF) immortalisation assay (HIMA). TP53 mutations arise in up to 30% of mutagen‐treated, immortalised HUFs; howeve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kucab, Jill E., Hollstein, Monica, Arlt, Volker M., Phillips, David H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Molecular Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215675/ https://www.ncbi.nlm.nih.gov/pubmed/27813088 http://dx.doi.org/10.1002/ijc.30504

Ejemplares similares

Characterising Mutational Spectra of Carcinogens in the Tumour Suppressor Gene TP53 Using Human TP53 Knock-in (Hupki) Mouse Embryo Fibroblasts
por: Hölzl-Armstrong, Lisa, et al.
Publicado: (2019)

TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts
por: Kucab, Jill E., et al.
Publicado: (2015)

TP53 and lacZ mutagenesis induced by 3-nitrobenzanthrone in Xpa-deficient human TP53 knock-in mouse embryo fibroblasts
por: Kucab, Jill E., et al.
Publicado: (2016)

Metabolic activation of 2‐amino‐1‐methyl‐6‐phenylimidazo [4,5‐b]pyridine and DNA adduct formation depends on p53: Studies in T rp53(+/+),T rp53(+/−) and T rp53(−/−) mice
por: Krais, Annette M., et al.
Publicado: (2015)

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
por: Løes, Inger Marie, et al.
Publicado: (2016)

Selective pericentromeric heterochromatin dismantling caused by TP53 activation during senescence
por: Mendez-Bermudez, Aaron, et al.
Publicado: (2022)

TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions
por: Shirole, Nitin H, et al.
Publicado: (2016)

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

Correction: TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions
por: Shirole, Nitin H, et al.
Publicado: (2017)

Defining function of wild-type and three patient-specific TP53 mutations in a zebrafish model of embryonal rhabdomyosarcoma
por: Chen, Jiangfei, et al.
Publicado: (2023)

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
por: Crane, Erin K., et al.
Publicado: (2015)

Mutagenicity of acrylamide and glycidamide in human TP53 knock-in (Hupki) mouse embryo fibroblasts
por: Hölzl-Armstrong, Lisa, et al.
Publicado: (2020)

TP53 drives invasion through expression of its Δ133p53β variant
por: Gadea, Gilles, et al.
Publicado: (2016)

Nutlin‐3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation
por: Hui, Wen, et al.
Publicado: (2018)

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
por: Meijer, A, et al.
Publicado: (2013)

tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish
por: Ignatius, Myron S, et al.
Publicado: (2018)

Comprehensive genomic profiling of high‐grade serous ovarian carcinoma from Chinese patients identifies co‐occurring mutations in the Ras/Raf pathway with TP53
por: Zhong, Fangfang, et al.
Publicado: (2019)

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
por: Aziz, Moammir H., et al.
Publicado: (2011)

miR‐548d‐3p/TP53BP2 axis regulates the proliferation and apoptosis of breast cancer cells
por: Song, Qiong, et al.
Publicado: (2015)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion
por: Fan, Yichao, et al.
Publicado: (2017)

TP53 mediated miR‐3647‐5p prevents progression of cervical carcinoma by targeting AGR2
por: Liu, Ronghua, et al.
Publicado: (2019)

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
por: Pozzo, Federico, et al.
Publicado: (2013)

Awakening p53 in senescent cells using nutlin-3
por: Schug, Thaddeus T.
Publicado: (2009)

Efficient expression of gene variants that harbour AGA codons next to the initiation codon
por: Zamora-Romo, Efraín, et al.
Publicado: (2007)

Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
por: Pizurica, Marija, et al.
Publicado: (2023)

The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/−) and TP53(−/−) cells
por: Willis, Alexandra J., et al.
Publicado: (2018)

Long noncoding RNA TCONS_00026334 is involved in suppressing the progression of colorectal cancer by regulating miR‑548n/TP53INP1 signaling pathway
por: Zhu, Mingming, et al.
Publicado: (2020)

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
por: Joshi, H, et al.
Publicado: (2012)

The genome as a record of environmental exposure
por: Nik-Zainal, Serena, et al.
Publicado: (2015)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

Crosstalk between tumor acidosis, p53 and extracellular matrix regulates pancreatic cancer aggressiveness
por: Czaplinska, Dominika, et al.
Publicado: (2022)

TP3, an antimicrobial peptide, inhibits infiltration and motility of glioblastoma cells via modulating the tumor microenvironment
por: Chen, Ying‐Fa, et al.
Publicado: (2020)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status
por: Wood, Anthony C, et al.
Publicado: (2022)

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
por: Wang, Y, et al.
Publicado: (2004)

TP53 mutations in vulval lichen sclerosus adjacent to squamous cell carcinoma of the vulva
por: Rolfe, K J, et al.
Publicado: (2003)

NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas
por: Meder, Lydia, et al.
Publicado: (2015)

Comparison of the metabolic activation of environmental carcinogens in mouse embryonic stem cells and mouse embryonic fibroblasts
por: Krais, Annette M., et al.
Publicado: (2015)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kr83kbpps93fdpmliqr9vtbhqs